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Abstract
Background: Ketamine produces schizophrenia-like behavioral phenotypes in healthy people. Prolonged ketamine effects 
and exacerbation of symptoms after the administration of ketamine have been observed in patients with schizophrenia. More 
recently, ketamine has been used as a potent antidepressant to treat patients with major depression. The genes and neurons 
that regulate behavioral responses to ketamine, however, remain poorly understood. Sp4 is a transcription factor for which 
gene expression is restricted to neuronal cells in the brain. Our previous studies demonstrated that Sp4 hypomorphic mice 
display several behavioral phenotypes relevant to psychiatric disorders, consistent with human SP4 gene associations with 
schizophrenia, bipolar disorder, and major depression. Among those behavioral phenotypes, hypersensitivity to ketamine-
induced hyperlocomotion has been observed in Sp4 hypomorphic mice.
Methods: In the present study, we used the Cre-LoxP system to restore Sp4 gene expression, specifically in either forebrain 
excitatory or GABAergic inhibitory neurons in Sp4 hypomorphic mice. Mouse behavioral phenotypes related to psychiatric 
disorders were examined in these distinct rescue mice.
Results: Restoration of Sp4 in forebrain excitatory neurons did not rescue deficient sensorimotor gating nor ketamine-induced 
hyperlocomotion. Restoration of Sp4 in forebrain GABAergic neurons, however, rescued ketamine-induced hyperlocomotion, 
but did not rescue deficient sensorimotor gating.
Conclusions: Our studies suggest that the Sp4 gene in forebrain GABAergic neurons regulates ketamine-induced hyperlocomotion.
Keywords: GABAergic, genetic rescue, ketamine, locomotor activity, Sp4
Introduction
Sp4 is a transcription factor that recognizes GC-rich sequences 
in the “CpG islands” around the promoters of many genes 
(Heisler et  al., 2005). In contrast to the Sp1 gene, Sp4 gene 
expression is restricted to neuronal cells in the brain (Supp 
et al., 1996; Zhou et al., 2005). Our previous studies found that 
Sp4 hypomorphic mice displayed several behavioral phenotypes 
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relevant to psychiatric disorders, including deficits in prepulse 
inhibition and hypersensitivity to ketamine (Zhou et al., 2005, 
2007, 2010). In humans, the SP4 gene was reported to be spo-
radically deleted in patients with schizophrenia (Tam et  al., 
2010; Zhou et al., 2010), and the SP4 protein is reduced in the 
post-mortem brains of bipolar patients (Pinacho et  al., 2011). 
Additionally, human genetic studies reported the association 
of the SP4 gene with bipolar disorder, schizophrenia, and major 
depression (Shyn et al., 2009; Zhou et al., 2009; Shi et al., 2010; 
Greenwood et al., 2011). These studies suggest the Sp4 hypomor-
phic mice as a promising mouse genetic model for human psy-
chiatric disorders.
Administration of ketamine, a noncompetitive N-methyl-D-
aspartate (NMDA) receptors antagonist, induces behaviors that 
resemble several aspects of psychiatric disorders in healthy 
people (Krystal et al., 1994; Xu et al., 2015). Prolonged ketamine 
effects and exacerbation of symptoms were reported in schizo-
phrenia patients after administration of ketamine (Lahti et al., 
1995; Malhotra et al., 1997; Holcomb et al., 2005). On the other 
hand, ketamine was recently found to act as a potent antide-
pressant that provides rapid relief to patients who are resistant 
to treatment with classical antidepressants (Zarate et al., 2006; 
Price et al., 2009; aan het Rot et  al., 2010; Diazgranados et al., 
2010; Li et al., 2010). In rodents, ketamine also disrupts prepulse 
inhibition of startle (PPI), a form of sensorimotor gating that is 
deficient in patients with either schizophrenia or bipolar disor-
der, but not in patients with depression (Braff et al., 2001; Geyer, 
2006). It is unclear however, what genes and neurons are the key 
regulators of such responses to ketamine.
Sp4 hypomorphic mice have robust behavioral phenotypes 
such as deficient PPI and hypersensitivity to ketamine-induced 
hyperlocomotion (Ji et al., 2013). By taking advantage of a genetic 
rescue strategy used in the generation of Sp4 hypomorphic mice 
(Zhou et al., 2005), we restored Sp4 expression in forebrain excit-
atory and GABAergic inhibitory neurons, respectively. Deficient 
PPI and ketamine-induced hyperlocomotion were examined in 
the two different neuron-specific Sp4 rescue mouse lines.
Materials and Methods
Mouse Strains and Breeding
Following the recommendation of the Banbury Conference on 
Genetic Background in Mice (Banbury, 1997) to use the F1 genetic 
background, we generated Sp4 hypomorphic mice on an F1 
129S/Black Swiss genetic background for behavioral studies, as 
previously described (Ji et  al., 2013). The Emx1-Cre mouse line 
(stock number: 005628) and Dlx6a-Cre mouse line (stock number: 
008199) were purchased from Jackson laboratory. Both lines were 
backcrossed with Black Swiss mice for more than six genera-
tions. Each Cre line was then bred with Sp4 heterozygous mice on 
a Black Swiss background to obtain double heterozygous mice. 
The double heterozygous mice were finally bred with Sp4 het-
erozygous mice on a 129S background to obtain F1 generation 
mice (Figure 1S). All F1 Sp4 heterozygous mice were sacrificed, 
and the remaining four genotypes were used for molecular and 
behavioral analyses (Supplemental Table I). Mice were housed 
in a climate-controlled animal colony with a reversed day/night 
cycle. Food (Harlan TeklabI) and water were available ad libitum, 
except during behavioral testing. Behavioral testing began when 
mice were 3 months old with PPI and ketamine-induced loco-
motor activity tests separated by at least 2 weeks. All testing 
procedures were approved by the UCSD Animal Care and Use 
Committee (permit number: A3033-01) prior to the onset of the 
experiments. Mice were maintained in American Association for 
Accreditation of Laboratory Animal Care–approved animal facil-
ities at UCSD and the local Veteran’s Administration Hospital. 
These facilities meet  all Federal and State requirements for 
animal care.
LacZ Staining
20 µm thick cryostat sections were cut from fresh adult mouse 
brains. The sections were fixed, permeabilized, and stained as 
previously described (Zhou et al., 2005).
Western Blot
Total protein was extracted from mouse cortices and striata 
and Western blot analyses were subsequently performed as 
described (Ji et al., 2014). Anti-Sp4 antibody was purchased from 
Santa Cruz Biotechnology (sc-13019, sc-645).
Immunohistochemical Analysis
Adult mice were anesthetized with carbon dioxide, and per-
fused transcardially with 2% phosphate buffered saline para-
formaldehyde. Mouse brains were dissected out and further 
fixed in 4% paraformaldehyde solution at 4°C for 24 hrs. 
Paraffin sections were generated. Sequential chromogenic 
immunohistochemistry was conducted to examine the co-
localization of Sp4 protein with Gad67 protein, a marker for 
GABAergic neurons in mouse cortex, as described by Kim et al. 
(2012).
Prepulse Inhibition
Startle reactivity and prepulse inhibition (PPI) were measured 
with startle chambers (SR-LAB, San Diego Instruments) as 
described by Ji et al. (2013). The background noise level was 65 
dB, and the pulse was 120 dB for 40 ms. The prepulse intensities 
were 69, 73, and 81 dB (4, 8, and 16 dB above the 65-dB back-
ground noise, respectively), delivered 80 ms before the pulse. 
The test session began and ended with five presentations of the 
“pulse-alone” trial. In between, each acoustic or “no stimulus” 
(65 dB background noise only) trial type was presented ten times 
in a pseudo-random order. The amount of PPI was calculated as 
a percentage score for each acoustic prepulse trial: %PPI = 100% 
× {1 - [(Startle response for “prepulse + pulse”)/(Startle response 
for “pulse-alone”)]}.
Video-Tracking Locomotion Tests
Locomotor activity was measured using the Video-Tracker (VT) 
system as previously described (Ji et al., 2013). Mice were tested 
during their dark period with lights on for the entire duration 
of the test. They were first acclimated to the testing room for 
60 min. Then, they were placed into white plastic enclosures 
(41 × 41 × 34 cm3), surrounded by an opaque plastic curtain. 
A video camera, mounted 158 cm above the enclosures, gener-
ated the signal for the Polytrack digitizer (San Diego Instruments). 
The position of each animal (x, y; in pixels) was sampled with a 
frequency of 18.18 Hz, which was used to generate a coordinate 
file (x, y, t) consisting of the x-location, y-location, and the dura-
tion (time t) spent in that location. After acclimation, mice were 
placed in their enclosures for 30 min of habituation. They then 
received ketamine (described below) and were placed back in 
their enclosures for another 60 min.
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Ketamine
Ketamine was dissolved in saline and administered i.p. at a vol-
ume of 5 ml/kg after 30 min habituation in the VT arena (Brody 
et al., 2003). The doses of ketamine were determined from the 
same F1 genetic background mouse in previous studies (Ji et al., 
2013). A  within-subjects crossover design was used for drug 
studies, with 2 weeks between drug treatments.
Statistical Analysis
Repeated measures analysis of variance with genotype as a 
between-subjects factor and drug treatment, block, and prepulse 
intensity as within-subjects factors were performed on the %PPI 
data and total distance traveled. Post hoc analyses were carried 
out using Newman-Keuls or Tukey’s test. Alpha level was set to 
0.05. No outliers were detected or removed from the analysis. All 
statistical analyses were carried out using the BMDP statistical 
software (Statistical Solutions Inc.).
Results
Generation of Neuron-Specific Sp4 Rescue Mice
Mouse Emx1 (Briata et al., 1996) and Dlx5/6 (Robledo et al., 2002) 
expression are first detected at embryonic day 9.5 (E9.5) and E8.5, 
respectively. Forebrain excitatory neurons originate from the 
Emx1 cell lineage (Gorski et al., 2002), while forebrain GABAergic 
neurons are derived from the Dlx5/6 cell lineage (Monory et al., 
2006). Since mouse Sp4 expression starts around E9.5 (Supp et al., 
1996), the Cre driven by Emx1 and Dlx5/6 genes will restore the 
Sp4 gene during the entire development of forebrain excitatory 
Figure 1. Restoration of rat Sp4 gene in forebrain excitatory neurons and GABAergic neurons, respectively. (A) A nuclear LacZ expression cassette was capped with a 
splicing acceptor and further flanked by two Lox P sites. The Lox P flanked LacZ was inserted in the first intron of mouse Sp4 gene. Expression of LacZ gene revealed that 
the Sp4 gene is specifically expressed in neuronal cells in mouse brain. After breeding with Emx1-Cre and Dlx6a-Cre mouse lines, the LacZ gene cassette was excised in 
forebrain excitatory neurons and GABAergic neurons, respectively. The removal of the LacZ cassette allows expression of the downstream rat Sp4 gene that was also 
capped with a splicing acceptor to splice with mouse exon 1 to generate a functional full-length Sp4 gene. The absence of blue staining in neuronal cells indicates 
restoration of the Sp4 gene. Because mouse cortices predominantly consist of excitatory neurons, LacZ blue staining almost completely disappeared in the cortices of 
Sp4 hypomorphic mice carrying the Emx1-Cre gene. In contrast, mouse striata predominantly contains GABAergic neurons, the LacZ blue staining almost completely 
disappeared in the striata of Sp4 hypomorphic mice carrying Dlx6a-Cre gene. (B) Under higher magnification, neurons that were not derived from the Emx1 lineage 
remain blue in the cortex of Sp4 hypomorphic mice carrying Emx1-Cre gene. Many of them are GABAergic neurons.
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and GABAergic neurons, respectively. In F1 Sp4 homozygous 
mice carrying either the Emx1-Cre or Dlx6a-Cre (Dlx5/6-Cre) gene 
(Figure S1), the nuclear LacZ cassette was excised to restore Sp4 
expression in each cell lineage (Figure 1). Consistent with previous 
reports on Emx1-Cre expression (Gorski et al., 2002), introduction 
of Emx1-Cre into Sp4 heterozygous mice abolished LacZ staining 
in both cortical and hippocampal excitatory neurons (Figure 1A). 
Under higher magnification, many LacZ blue spots remained in 
both the cortex and hippocampus. They presumably consisted of 
GABAergic and other types of neurons (Figure 1B). Introduction of 
Dlx6a-Cre into Sp4 heterozygous mice abolished LacZ staining in 
striatal GABAergic neurons. Because cortical GABAergic neurons 
are a minority group of neurons scattered across the cortex, the 
disappearance of LacZ staining in these GABAergic neurons can-
not be directly visualized in the cortices of Sp4 heterozygous mice 
carrying a Dlx6a-Cre transgene. However, Dlx6a-Cre expression 
in cortical GABAergic neurons was readily detected in the same 
Dlx6a-Cre mouse line when breeding with ROSALacZ (Gtrosa26tm1Sor) 
reporter mice (http://www.informatics.jax.org/recombinase/specif
icity?id=MGI:3758328&systemKey=4856356).
Western blot provided validation of restoration of the Sp4 tran-
scription factor in the cortex of the [Sp4 Hypo/Hypo; Emx1+/+(Cre)] rescue 
mice (Figure  2A). Restoration of the Sp4 transcription factor was 
also confirmed in the striata of [Sp4 Hypo/Hypo; Tg(Dlx6a-Cre)] rescue 
mice (Figure 2B). An increased level of Sp4 protein was observed 
in the cortices of GABAergic Sp4 rescue mice [Sp4 Hypo/Hypo; Tg(Dlx6a-
Cre)]. Nevertheless, this increase was inconclusive because there 
are fewer GABAergic neurons than excitatory neurons in mouse 
cortices. To examine whether Sp4 expression is specifically restored 
in the cortical GABAergic neurons of Sp4 rescue mice [Sp4 Hypo/Hypo; 
Figure 2. Sp4 expression in neuron-specific Sp4 rescue mice. (A) Western blot confirmed expression of Sp4 protein in the cortices of rescue mice [Sp4Hypo/Hypo; 
Emx1+/+(Cre)]. (B) Western blot confirmed expression of Sp4 protein in the striata of rescue mice [Sp4Hypo/Hypo; Tg(Dlx6a-Cre)]. A low level of Sp4 protein in the cortices 
of the rescue mice likely comes from restored Sp4 expression in cortical GABAergic neurons. (C) Co-localization between Sp4 and Gad67 proteins was analyzed using 
sequential chromogenic immunohistochemistry in the cortices of Sp4 rescue mice with either the Emx1-Cre or the Dlx6a-Cre gene. In Sp4 hypomorphic mice carrying 
the Emx1-Cre gene, Sp4 protein expression was restored only in cortical excitatory neurons, but not in Gad67-positive cortical GABAergic inhibitory neurons. In contrast, 
Sp4 protein expression was only detected in Gad67-positive cortical GABAergic neurons in Sp4 hypomorphic mice carrying the Dlx6a-Cre gene. Expression of Sp4 and 
Gad67 proteins was pseudocolored into green and red, respectively, and superimposed for their co-localization (Kim et al., 2012). Scale bar: 25 µm.
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Tg(Dlx6a-Cre)], we conducted sequential immunohistochemical 
analyses of Sp4 and Gad67 proteins (Kim et al., 2012). Sp4 protein 
was detected only in the Gad67-positive GABAergic interneurons in 
the Sp4 rescue mice carrying the Dlx6a-Cre gene (Figure 2C). There 
is no detectable Sp4 protein in the surrounding Gad67-negative 
neurons, which are mostly cortical excitatory neurons. In contrast, 
most cortical neurons, except Gad67-positive interneurons, express 
Sp4 protein in the Sp4 rescue mice carrying the Emx1-Cre gene.
Behavioral Characterization of the Emx1-Cre 
Rescue Mice
Deficits in PPI and ketamine-induced hyperlocomotion were exam-
ined in the two different neuron-specific Sp4 rescue mice. In the 
Emx1-Cre rescue cohort, startle reactivity (Supplemental Table II) and 
PPI (Supplemental Table III and IV) were investigated. Sp4 hypomor-
phic mice showed significantly reduced PPI [F(1,80)=18.23, p < 0.0001; 
Figure 3A], which was not rescued by restoration of the Sp4 gene 
in forebrain excitatory neurons in [Sp4 Hypo/Hypo; Emx1 +/+(Cre)] rescue 
mice [Sp4 X Emx1-Cre interaction, F(1,80) < 1, ns]. No sex effects were 
observed. We examined the locomotor response of these mice to 
ketamine (50 mg/kg) using video-tracking (VT) equipment. Before 
ketamine treatment, there was no significant Sp4 gene effect on 
distance traveled during habituation. After ketamine injection, Sp4 
hypomorphic mice exhibited significantly more ketamine-induced 
hyperactivity compared to wild-type controls {Figure 3B; Sp4 X keta-
mine interaction [F(1,79)= 12.97, p = 0.0006] on distance traveled}. No 
Sp4 X Emx1-Cre X ketamine interaction was detected [F(1,79) < 1, ns]. 
Figure 3. Characterization of rescue mice with restoration of Sp4 gene only in forebrain excitatory neurons. Male and female mice were balanced in each genotype. 
There were 18 wild-type (Sp4+/+; Emx1+/+), 20 Sp4 hypomorphic (Sp4Hypo/Hypo; Emx1+/+), 19 wild-type carrying Emx1-Cre (Sp4+/+; Emx1+/+(Cre)), and 27 rescue mice 
(Sp4Hypo/Hypo; Emx1+/+(Cre)) for behavioral analyses. (A) Prepulse inhibition was conducted in these mice. No sex effect was found. Sp4 hypomorphic mice displayed 
prepulse inhibition of startle (PPI) deficits across three different prepulse intensities compared to wild-type mice, regardless of the presence or absence of the Emx1-
Cre gene. (B) All mice were habituated for 30 min before injection of ketamine (50 mg/kg). Injection of ketamine significantly increased locomotor activity in all four 
genotypes. A significantly larger increase of locomotor activity was observed in Sp4 hypomorphic mice, with or without the Emx1-Cre gene, than in wild-type mice 
{Sp4 X ketamine interaction [F(1,79)= 12.97, p = 0.0006] on distance traveled}. However, there was no Sp4 X Emx1-Cre X ketamine interaction. Error bar: standard error 
of the mean.
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The rescue mice [Sp4 Hypo/Hypo; Emx1 +/+(Cre)] displayed similar ketamine-
induced hyperlocomotion as the (Sp4 Hypo/Hypo; Emx1+/+) Sp4 hypomor-
phic mice after ketamine injection, suggesting that there was no 
rescue of ketamine hypersensitivity.
Behavioral Characterization of the Dlx6a-Cre 
Rescue Mice
In the Dlx6a-Cre rescue cohort, startle reactivity (Supplemental 
Table V) and PPI (Supplemental Table VI and VII) were 
investigated. Sp4 hypomorphic mice exhibited reduced PPI 
[F(1,85) = 9.73, p = 0.002; Figure 4A]. However, no Sp4 X Dlx6a-Cre 
interaction was detected [F(1,85) = 1.38, ns], with the [Sp4 Hypo/Hypo; 
Tg(Dlx6a-Cre)] rescue mice exhibiting similar PPI deficits to Sp4 
hypomorphic mice. The response to ketamine was subsequently 
examined with the VT locomotion test. No significant Sp4 effect 
was observed during habituation. After ketamine injection, a 
significant Sp4 X ketamine interaction [F(1,85) = 14.54, p < 0.001] 
was observed (Figure 4B). Interestingly, there was a significant 
Sp4 X Dlx6a-Cre X ketamine interaction [F(1,85)=7.44, p = 0.008]. 
Figure 4. Prevention of ketamine-induced hyperlocomotion in rescue mice with restoration of Sp4 gene only in forebrain GABAergic neurons. Male and female mice 
were balanced in each genotype. There were 9 wild-type (Sp4+/+), 13 Sp4 hypomorphic (Sp4Hypo/Hypo), 46 wild-type carrying Dlx6a-Cre [Sp4+/+; Tg(Dlx6a-Cre)], and 21 
rescue mice [Sp4Hypo/Hypo; Tg(Dlx6a-Cre)] for behavioral analyses. Our breeding generated fewer wild-type and Sp4 hypomorphic mice. More rescue mice and the 
control wild-type mice carrying the Dlx6a-Cre transgene were produced. (A) Prepulse inhibition was examined in all four genotypes of mice. There was no sex effect on 
prepulse inhibition of startle (PPI). Sp4 hypomorphic mice displayed PPI deficits across three different prepulse intensities compared to wild-type mice. No Sp4 X Dlx6a-
Cre interaction was observed. (B) After 30 min habituation in VT chamber, mice were injected with ketamine (50 mg/kg). As expected, Sp4 hypomorphic mice displayed 
significantly more locomotor activity after ketamine injection [F(1,85)=14.54, p < 0.001]. Post hoc analysis revealed more distance traveled in the Sp4 hypomorphic mice 
than wild-type mice at 10 (*p < 0.05), 20 (**p < 0.01), 30 (**p < 0.01), 40 (**p < 0.01), and 50 min (*p < 0.05) post–ketamine injection. A significant Sp4 X Dlx6a-Cre X ketamine 
interaction was found [F(1,85)=7.44, p = 0.008]. Post hoc analysis revealed significant differences in the distance traveled between the Sp4 hypomorphic mice in the 
absence or presence (rescue) of the Dlx6a-Cre transgene at 20 (#p < 0.01), 30 (#p < 0.01), and 40 (#p < 0.01) min post-ketamine injection. The rescue mice [Sp4 Hypo/Hypo; 
Tg(Dlx6a-Cre)] displayed no difference in locomotor activity from the wild-type mice carrying the Dlx6a-Cre gene, suggesting an almost complete rescue of the excessive 
response to ketamine. Error bar: standard error of the mean.
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The rescue mice [Sp4 Hypo/Hypo; Tg(Dlx6a-Cre)] displayed the same 
time-course pattern of locomotive hyperactivity as the control 
mice [Sp4 +/+; Tg(Dlx6a-Cre)] after ketamine injection, suggest-
ing that restoration of Sp4 in forebrain GABAergic neurons is 
sufficient to rescue ketamine-induced hyperlocomotion in Sp4 
hypomorphic mice.
Discussion
Genetic manipulations are powerful tools for disentangling 
complex phenotypic profiles. We previously demonstrated that 
a full restoration of the Sp4 gene in the whole animal by crossing 
with a protamine-cre mouse line rescued the complete pheno-
typic profile seen in Sp4 hypomorphic mice (Zhou et al., 2005). 
Conventional and conditional gene-knockout strategies can 
determine whether a gene is necessary for a particular pheno-
type in a specific type of cells. Conditional rescue of a phenotype 
in knockout mice via restoration of the gene in only one specific 
cell type can determine whether the gene in that specific cell 
type is necessary and sufficient for controlling the phenotype. 
Many behaviors are complex, and likely modulated by interac-
tions between different types of neurons from different brain 
regions. Given that different types of neurons are involved in 
the modulation of behavior, it is not surprising that Sp4 gene 
restoration in only one specific type of neuron may not be suf-
ficient to rescue the full behavioral profile. Indeed, we failed 
to rescue deficient PPI in Sp4 hypomorphic mice regardless of 
whether the Sp4 gene was restored in forebrain excitatory neu-
rons or GABAergic neurons, although PPI was rescued previously 
when the Sp4 gene was rescued in the whole animal (Zhou et al., 
2005). Importantly, however, we found that restoration of the Sp4 
gene in GABAergic neurons was sufficient to rescue ketamine-
induced hyperlocomotion in the Sp4 hypomorphic mice.
Sp4 hypomorphic mice (Sp4 Hypo/Hypo) from the Dlx6a-Cre rescue 
cohort displayed a prolonged response to ketamine relative to 
the response in wild-type control mice. However, Sp4 hypomor-
phic mice (Sp4 Hypo/Hypo; Emx1+/+) from the Emx1-Cre rescue cohort 
had a similar time-course response to ketamine with their sib-
ling wild-type mice. The prolonged response to ketamine in the 
Sp4 hypomorphic mice from the Dlx6a-Cre rescue cohort is a 
more typical response of Sp4 hypomorphic mice according to 
our previous studies (Ji et al., 2013). Why did the same dosage 
of ketamine not elicit a prolonged response to ketamine in the 
Sp4 hypomorphic mice from the Emx1-Cre rescue cohort? We 
speculate that there may be still subtle differences between the 
genetic backgrounds of the Emx1-Cre and Dlx6a-Cre mouse lines 
despite the fact that both Emx1-Cre and Dlx6a-Cre mouse lines 
were backcrossed for more than six generations. The genetic 
background of the Emx1-Cre rescue cohort may have been over-
all less sensitive to ketamine than that of the Dlx6a-Cre rescue 
cohort. We consider that different time-course responses to 
ketamine may be generated by differential ketamine sensitivi-
ties between mouse cohorts or different dosages of ketamine. 
Indeed, increasing dosages of ketamine produced more locomo-
tor activity and prolonged responses (Irifune et al., 1991). This 
observation may explain why the same dosage of ketamine 
generated different time-courses in the locomotor responses 
between the two different mouse cohorts.
Ketamine acts primarily, although not exclusively (Kapur 
and Seeman, 2002), as a noncompetitive antagonist of NMDA 
receptors that are present in both excitatory and GABAergic 
neurons in multiple brain regions. Cortical GABAergic inhibitory 
neurons have been suggested to be the primary targets of NMDA 
receptor antagonists (Moghaddam et al., 1997; Homayoun and 
Moghaddam, 2007). Our studies suggest that the mouse Sp4 gene 
is essential for forebrain GABAergic neurons to dampen locomo-
tor responses to ketamine. Reduced Sp4 expression may impair 
the ability of GABAergic neurons to control locomotor hyperac-
tivity in Sp4 hypomorphic mice after ketamine injection (Ji et al., 
2013). In contrast, the Sp4 gene expression appears dispensa-
ble in excitatory neurons in controlling the locomotor response 
to ketamine. Since the genetic restoration of the Sp4 gene in 
Dlx6a-Cre lineage cells starts from early embryogenesis, our 
studies cannot differentiate whether altered development and/
or function of forebrain GABAergic neurons are responsible for 
ketamine hypersensitivity in Sp4 hypomorphic mice. Although 
we did not find gross abnormalities in the brains of Sp4 hypo-
morphic mice (Zhou et al., 2005; Ji et al., 2013), we cannot rule 
out subtle structural alterations in GABAergic neurons. As for 
molecular mechanisms, the NMDA receptor has been proposed 
as the primary target of ketamine. The protein, but not mRNA, 
of Nmdar1, the obligatory subunit of NMDA receptors, was 
down-regulated in the brains of Sp4 hypomorphic mice (Zhou 
et al., 2010; Sun et al., 2015). Those findings, however, came from 
mouse brain tissue that contained different types of neurons 
and glial cells, and hence do not necessarily exclude the Nmdar1 
gene as a direct target of the Sp4 transcription factor in a small 
group of specific neurons. There is still a possibility that the Sp4 
transcription factor may directly regulate mRNA expression of 
the Nmdar1 gene in some forebrain GABAergic neurons (Krainc 
et al., 1998). Forebrain GABAergic neurons consist of striatal neu-
rons and different cortical GABAergic neurons. It remains to be 
investigated which subset of GABAergic neurons is responsible 
for the rescue effects observed here. Investigation of molecular 
mechanisms can eventually be conducted after identification of 
the critical GABAergic neurons. It should be kept in mind that 
other receptors and channels, in addition to NMDA receptors, 
may also mediate the effects of ketamine in Sp4 hypomorphic 
mice (Jamie Sleigha et  al., 2014). In the future, restoration of 
the Sp4 gene in forebrain GABAergic neurons via temporal and 
region-specific (e.g. cortex or striatum) control of Cre-mediated 
DNA recombination may clarify the role of development of 
GABAergic neurons and functions of regional GABAergic neu-
rons in controlling locomotor responses to ketamine.
Cortical GABAergic inhibitory interneurons have been pro-
posed to be the primary targets of NMDA receptor antagonists 
(Moghaddam et al., 1997; Homayoun and Moghaddam, 2007) and 
contribute to the pathogenesis of schizophrenia (Lewis et  al., 
2005; Lewis and Moghaddam, 2006). Abnormalities in GABA 
receptors have been reported in the brains of patients with 
schizophrenia, bipolar disorder, or major depression (Fatemi 
et  al., 2013). Ketamine produces schizophrenia-like behavioral 
phenotypes in healthy people and exacerbates symptoms in 
schizophrenia patients. Our studies suggest that SP4, deleted in 
some patients with schizophrenia, could be a missing piece that 
links a genetic susceptibility gene with ketamine hypersensitiv-
ity and abnormal function of GABAergic neurons in schizophre-
nia. The influence of the Sp4-GABAergic-ketamine pathway may 
not be limited to the regulation of locomotor activity in response 
to ketamine. Given that ketamine functions as a potent anti-
depressant, it will be interesting to investigate whether the 
Sp4-GABAergic-NMDA pathway may also be involved in the reg-
ulation of depressive behaviors. Indeed, our most recent studies 
suggested that Sp4 hypomorphic mice displayed depressive-like 
behaviors (Young et  al., 2015). In the future, such depressive-
like phenotypes will be examined after ketamine treatment 
in Sp4 hypomorphic mice with restoration of the Sp4 gene in 
GABAergic neurons.
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